Article thumbnail
Location of Repository



1Selective inhibition of the cyclooxygenase (cox)-2 isoen-zyme has been associated with an increase in adverse car-diovascular events, which resulted in the removal of rofecoxib from the market.1,2 In contrast, inhibition of cox-1 by aspirin has been associated with a reduction in adverse cardiovascu-lar events.3–5 Nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit cox-1 and cox-2 to varying degrees.6 Some studies have demonstrated that nonselective NSAIDs increase the hazard for adverse cardiovascular outcomes,7–11 whereas others have documented a reduced frequency of adverse car-diovascular events.7,11–14 The Safety of Non-Steroidal Anti-Inflammatory Drug Project recently concluded that important knowledge gaps exist, particularly with the traditional NSAIDs.15 Although the overall association of NSAIDs and cardiovascular risk remains uncertain, even less information i

Year: 2016
OAI identifier: oai:CiteSeerX.psu:
Provided by: CiteSeerX
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://circoutcomes.ahajournal... (external link)
  • http://circoutcomes.ahajournal... (external link)
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.